Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,256,555 papers from all fields of science
Search
Sign In
Create Free Account
PR-104
Known as:
PR104
A non-toxic, small-molecule, hypoxia-activated, 3,5-dinitrobenzamide nitrogen mustard pre-prodrug with potential antitumor activity. Upon intravenous…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
DNA
Broader (1)
Nitrogen Mustard Compounds
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives.
R. Singh
,
Sahil Kumar
,
D. Prasad
,
T. Bhardwaj
European journal of medicinal chemistry
2018
Corpus ID: 4811040
Highly Cited
2015
Highly Cited
2015
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
M. Konopleva
,
P. Thall
,
+25 authors
H. Kantarjian
Haematologica
2015
Corpus ID: 24721932
We previously demonstrated vast expansion of hypoxic areas in the leukemic microenvironment and provided a rationale for using…
Expand
Review
2014
Review
2014
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
C. Guise
,
A. Mowday
,
+6 authors
K. Ding
Chinese journal of cancer
2014
Corpus ID: 14152197
Hypoxia, a state of low oxygen, is a common feature of solid tumors and is associated with disease progression as well as…
Expand
Highly Cited
2011
Highly Cited
2011
Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104
J. Benito
,
Yue-xi Shi
,
+17 authors
M. Konopleva
PLoS ONE
2011
Corpus ID: 839324
Recent studies indicate that interactions between leukemia cells and the bone marrow (BM) microenvironment promote leukemia cell…
Expand
Highly Cited
2011
Highly Cited
2011
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
M. McKeage
,
Yongchuan Gu
,
+4 authors
M. Jameson
BMC Cancer
2011
Corpus ID: 12260661
BackgroundThe phosphate ester PR-104 is rapidly converted in vivo to the alcohol PR-104A, a nitrogen mustard prodrug that is…
Expand
Review
2010
Review
2010
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
C. Guise
,
M. Abbattista
,
+10 authors
A. Patterson
Cancer Research
2010
Corpus ID: 2597350
PR-104, currently in phase II clinical trials, is a phosphate ester pre-prodrug which is converted in vivo to its cognate alcohol…
Expand
Highly Cited
2010
Highly Cited
2010
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
M. Jameson
,
D. Rischin
,
+4 authors
W. Wilson
Cancer Chemotherapy and Pharmacology
2010
Corpus ID: 35209191
PurposePR-104 is a “pre-prodrug” designed to be activated to a dinitrobenzamide nitrogen mustard cytotoxin by nitroreduction in…
Expand
Highly Cited
2007
Highly Cited
2007
Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104
A. Patterson
,
D. Ferry
,
+10 authors
W. Wilson
Clinical Cancer Research
2007
Corpus ID: 8202074
Purpose: Hypoxia is a characteristic of solid tumors and a potentially important therapeutic target. Here, we characterize the…
Expand
Highly Cited
2007
Highly Cited
2007
Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
C. Guise
,
A. Wang
,
A. Theil
,
D. J. Bridewell
,
W. Wilson
,
A. Patterson
Biochemical Pharmacology
2007
Corpus ID: 46556602
Highly Cited
2007
Highly Cited
2007
Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
K. Hicks
,
Hilary Myint
,
+4 authors
W. Wilson
International Journal of Radiation Oncology…
2007
Corpus ID: 1616407
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE